United States

Biogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Biogen Announces First Patient Treated in Respond Study Evaluating Benefit of Spinraza® in Patients Treated with Zolgensma®

Lead Product(s): Nusinersen

Therapeutic Area: Genetic Disease Product Name: Spinraza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

Details:

The RESPOND study aims to evaluate if Spinraza can benefit SMA patients who have experienced a ‘suboptimal’ response to Zolgensma (onasemnogene abeparvovec). It will be conducted at around 20 sites globally, with researchers aiming to enrol up to 60 children with SMA.

Biogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Biogen to Initiate Phase 4 Respond Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma

Lead Product(s): Nusinersen

Therapeutic Area: Genetic Disease Product Name: Spinraza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

The RESPOND study will seek to understand if the proven efficacy of SPINRAZA and its continuous production of SMN protein may also benefit patients previously treated with gene therapy.